Reviews Votrient


No reviews yet.

Votrient Drug Description
VOTRIENT
(pazopanib) Tablets

WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor
hepatic function and interrupt, reduce, or discontinue dosing as recommended.
[See WARNINGS AND
PRECAUTIONS.]

DRUG DESCRIPTION
VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented
as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2S•HCl
and a molecular weight of 473.99. Pazopanib hydrochloride has the following
chemical structure:








Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.
Tablets of VOTRIENT are for oral administration. Each 200 mg tablet of VOTRIENT contains 216.7 mg of pazopanib hydrochloride, equivalent to 200 mg of pazopanib free base.
The inactive ingredients of VOTRIENT are: Tablet Core: Magnesium stearate,
microcrystalline cellulose, povidone, sodium starch glycolate. Coating:
Gray film-coat: Hypromellose, iron oxide black, macrogol/polyethylene glycol
400 (PEG 400), polysorbate 80, titanium dioxide.
Last reviewed on RxList: 6/1/2010




Votrient Drug Description
VOTRIENT
(pazopanib) Tablets

WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor
hepatic function and interrupt, reduce, or discontinue dosing as recommended.
[See WARNINGS AND
PRECAUTIONS.]

DRUG DESCRIPTION
VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented
as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2S•HCl
and a molecular weight of 473.99. Pazopanib hydrochloride has the following
chemical structure:








Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.
Tablets of VOTRIENT are for oral administration. Each 200 mg tablet of VOTRIENT contains 216.7 mg of pazopanib hydrochloride, equivalent to 200 mg of pazopanib free base.
The inactive ingredients of VOTRIENT are: Tablet Core: Magnesium stearate,
microcrystalline cellulose, povidone, sodium starch glycolate. Coating:
Gray film-coat: Hypromellose, iron oxide black, macrogol/polyethylene glycol
400 (PEG 400), polysorbate 80, titanium dioxide.
Last reviewed on RxList: 6/1/2010




Votrient Drug Description
VOTRIENT
(pazopanib) Tablets

WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor
hepatic function and interrupt, reduce, or discontinue dosing as recommended.
[See WARNINGS AND
PRECAUTIONS.]

DRUG DESCRIPTION
VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented
as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2S•HCl
and a molecular weight of 473.99. Pazopanib hydrochloride has the following
chemical structure:








Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.
Tablets of VOTRIENT are for oral administration. Each 200 mg tablet of VOTRIENT contains 216.7 mg of pazopanib hydrochloride, equivalent to 200 mg of pazopanib free base.
The inactive ingredients of VOTRIENT are: Tablet Core: Magnesium stearate,
microcrystalline cellulose, povidone, sodium starch glycolate. Coating:
Gray film-coat: Hypromellose, iron oxide black, macrogol/polyethylene glycol
400 (PEG 400), polysorbate 80, titanium dioxide.
Last reviewed on RxList: 6/1/2010




Votrient Drug Description
VOTRIENT
(pazopanib) Tablets

WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor
hepatic function and interrupt, reduce, or discontinue dosing as recommended.
[See WARNINGS AND
PRECAUTIONS.]

DRUG DESCRIPTION
VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented
as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2S•HCl
and a molecular weight of 473.99. Pazopanib hydrochloride has the following
chemical structure:








Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.
Tablets of VOTRIENT are for oral administration. Each 200 mg tablet of VOTRIENT contains 216.7 mg of pazopanib hydrochloride, equivalent to 200 mg of pazopanib free base.
The inactive ingredients of VOTRIENT are: Tablet Core: Magnesium stearate,
microcrystalline cellulose, povidone, sodium starch glycolate. Coating:
Gray film-coat: Hypromellose, iron oxide black, macrogol/polyethylene glycol
400 (PEG 400), polysorbate 80, titanium dioxide.
Last reviewed on RxList: 6/1/2010




Votrient Drug Description
VOTRIENT
(pazopanib) Tablets

WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical studies. Monitor
hepatic function and interrupt, reduce, or discontinue dosing as recommended.
[See WARNINGS AND
PRECAUTIONS.]

DRUG DESCRIPTION
VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented
as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide
monohydrochloride. It has the molecular formula C21H23N7O2S•HCl
and a molecular weight of 473.99. Pazopanib hydrochloride has the following
chemical structure:








Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.
Tablets of VOTRIENT are for oral administration. Each 200 mg tablet of VOTRIENT contains 216.7 mg of pazopanib hydrochloride, equivalent to 200 mg of pazopanib free base.
The inactive ingredients of VOTRIENT are: Tablet Core: Magnesium stearate,
microcrystalline cellulose, povidone, sodium starch glycolate. Coating:
Gray film-coat: Hypromellose, iron oxide black, macrogol/polyethylene glycol
400 (PEG 400), polysorbate 80, titanium dioxide.
Last reviewed on RxList: 6/1/2010





Other reviews about Votrient on wordpress

Pegintron To Be Discussed At FDA's ODAC October 5, 2009 Meeting?
  by condor
At least one published report of an Advisory Committee meeting to, among other matters, discuss Schering-Plough's Pegintron, for [additional] melanoma indications (and some earlier Schering-Plough hedging on […]


Pegintron ODAC Meeting on October 5, 2009: Confirmed by FDA
  by condor
So the overnight UK pressers had it right. There will be a meeting, all-day on October 5, 2009: . . . .The committee will discuss: (1) supplemental […]


For A Mere $140(!), You Too Can Watch A Grainy, Low-Res Webcast of the ODAC Meeting on Monday
  by condor
Gee -- I am not sure that's a compelling value, vis-a-vis streaming web-based re-runs of "Gilligan's Island" (free, of course!). In any event, here is a link to […]


FDA Approves New Treatment for Advanced Form of Kidney Cancer
  by neurologist
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation […]


Diplomat Pharmacy Provides Votrientâ„¢ To Treat Patients With Renal Cell Carcinoma
  by diplomatsp
Diplomat Specialty Pharmacy provides the medication Votrientâ„¢, used to treat patients with renal cell carcinoma, a form of kidney cancer. RCC is a common malignancy of the kidney and is […]


The FDA releases their tally for 2009
  by Jeffrey Clark
The past nine months have been a remarkable turnaround by the FDA, mostly charted by Dr. Margaret Hamburg in her role as President Obama’s appointed FDA Commissioner.  […]


GSK to increase headcount, introduce more products
  by INDOLINK Consulting (es)
Mumbai: Multinational drug-maker GlaxoSmithKline Pharmaceuticals Ltd is set to increase its field-force, and introduce several products including patent-protected ones, over the next 12-18 months. Having added about 200 people […]


New Drug Promising for Advanced Thyroid Cancer
  by nalonsospc
By Steven ReinbergHealthDay Reporter FRIDAY, Sept. 17 (HealthDay News) -- A targeted drug called pazopanib could prove effective against difficult-to-treat cases of thyroid cancer cases, researchers say. Most thyroid cancers […]


New Drug Promising for Advanced Thyroid Cancer (HealthDay)
  by myxtendlife
FRIDAY, Sept. 17 (HealthDay News) -- A targeted drug called pazopanib could […]


Glaxo kidney cancer drug shrinks thyroid tumors: study (Reuters)
  by myxtendlife
CHICAGO (Reuters) – In a small study, GlaxoSmithKline's cancer drug Votrient helped […]



Other reviews about Votrient on web:

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. VOTRIENT


Learn about the prescription medication Votrient (Pazopanib Tablets), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Votrient (Pazopanib Tablets) Drug Information: Uses, Side Effects ...


Votrient (pazopanib) is used to treat renal cell carcinoma (kidney cancer). Includes Votrient side effects, interactions and indications. Votrient Information from Drugs.com


Accurate, FDA approved Votrient information for healthcare professionals and patients - brought to you by Drugs.com. Votrient Official FDA information, side effects and uses.


GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has approved VOTRIENT(TM) (pazopanib) to treat patients with advanced renal cell ... FDA Approves GlaxoSmithKline's VOTRIENT(TM) For Advanced Renal ...


The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. FDA Approves New Treatment for Advanced Form of Kidney Cancer


This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates. FDA approves GlaxoSmithKline’s Votrient™ for advanced renal ...


HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VOTRIENT safely and effectively. See full prescribing information for ... HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not ...


Organized by therapeutic area, this comprehensive listing of FDA-Approved Drugs by the Food and Drug Administration features facts on clinical trial results, side effects and ... Newly Approved Drug Therapies (1066) Votrient (pazopanib ...


The Products section includes non-promotional information about GSK products, including prescription medicines, consumer healthcare products and vaccines. Votrient - Prescription medicines - Our products - GlaxoSmithKline





Featured Reviews

Reviews Zocor

Zocor Drug Description ZOCOR (simvastatin) Tablets DRUG DESCRIPTION What are the possible side effects of simvastatin (Zocor)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Claforan

Claforan Drug Description CLAFORAN® Sterile (cefotaxime) for Injection, USP and Injection (cefotaxime) Injection, USP To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLAFORAN (cefotaxime...
Read More  |  Review This
Reviews Renacidin

Renacidin Drug Description Renacidin® (Citric Acid, Glucono-delta-lactone and Magnesium Carbonate irrigation) DRUG DESCRIPTION Renacidin® (Citric Acid, Glucono-delta-lactone and Magnesium Carbonate) Irrigation is a sterile, non-pyrogenic...
Read More  |  Review This
Reviews Japanese Encephalitis Virus Vaccine Inactivated

Je-Vax Drug Description JE-VAX® Japanese Encephalitis Virus Vaccine Inactivated DRUG DESCRIPTION What are the possible side effects of this vaccine (Je-Vax)? You should not receive a booster vaccine if you had a life-threatening...
Read More  |  Review This
Reviews Theophylline in 5% Dextrose Injection Viaflex

Theophylline in 5% Dextrose Injection Viaflex Drug Description THEOPHYLLINE IN DEXTROSE (theophylline anhydrous) Injection, Solution USP in Plastic Container VIAFLEX Plus Container DRUG DESCRIPTION Theophylline in 5% Dextrose Injection,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....